Company Profile
Lifeward is a US-Israel based manufacturer of neurorehabilitation and mobility devices, headquartered in Yokneam Illit, Israel, with US headquarters in Hudson, Massachusetts, USA. Founded in 2001 as Argo Medical Technologies (later ReWalk Robotics), the company rebranded to Lifeward in January 2024 and operates as a publicly traded entity on Nasdaq (LFWD), serving rehabilitation markets in the United States, Europe, and Israel.
Core Products ＆ Technologies
Wearable Exoskeleton Systems
• ReWalk 7 Personal Exoskeleton: Seventh-generation FDA-cleared and CE-marked hip-knee powered exoskeleton for spinal cord injury, featuring cloud connectivity, crutch control, smartwatch mode selection, and seamless stair/curb navigation
• ReWalk Rehabilitation System: Clinic-optimized exoskeleton for high-volume gait training and patient assessment
• ReStore Exo-Suit: Soft robotic exosuit for functional gait assistance in stroke rehabilitation
Anti-Gravity ＆ FES Therapy Systems
• AlterG Anti-Gravity Systems: Differential air pressure treadmills and body-weight support technologies for gait and balance training; acquired August 2023
• MyoCycle FES Systems: Functional electrical stimulation cycling therapy for neurological and orthopedic rehabilitation; distributed in partnership with Myolyn
Upper-Limb Neurorehabilitation
• Upper Body Powered Exoskeleton: Technology with integrated AI capabilities designed to assist individuals with upper-limb mobility limitations; agreement entered in Q1 2026, anticipated commercial launch within 18 to 24 months following regulatory approvals
Market Position ＆ Certifications
Lifeward holds a leading position in the global neurorehabilitation robotics market, competing with Myomo and Hocoma in rehabilitation robotics and exoskeletons. Key strengths include:
• 25+ years of robotics engineering heritage in powered exoskeletons
• Regulatory compliance: FDA 510(k) cleared (ReWalk Personal and Rehabilitation systems); CE marked (ReWalk 7); CMS national reimbursement policy established 2024
• Real-world safety evidence: ASIA 2026 presentation of longitudinal data (2013–2025) showing lower-extremity fracture prevalence declined from 3% to 0.3%<
• Commercial coverage: Prior authorization approvals from three of the largest Medicare Advantage insurers, including Aetna, Humana, and UnitedHealthcare
Corporate Timeline
2001 — Founded as Argo Medical Technologies in Israel to develop powered exoskeletons
2014 — FDA clearance granted for ReWalk Personal Exoskeleton for spinal cord injury
2023 — Acquired AlterG, Inc.; FDA clearance for ReWalk 6.0 stair and curb navigation
2024 — Rebranded as Lifeward Ltd; CMS established national reimbursement policy for personal exoskeletons
2025 — Launched ReWalk 7 Personal Exoskeleton in the US; CE mark approved for European sale
2026 — Entered agreement to acquire upper body powered exoskeleton technology for stroke rehabilitation; appointed Dr. Keith D. Rose as Chief Medical Officer in May; presented decade-long ReWalk safety data at ASIA conference
Target Markets ＆ Applications
• Spinal cord injury mobility: ReWalk exoskeletons for ambulation and functional independence in clinic, home, and community settings
• Stroke rehabilitation: ReStore Exo-Suit and upper body exoskeleton for gait recovery and upper-limb functional restoration
• Neurorehabilitation therapy: AlterG and MyoCycle systems for gait training, balance, and muscle conditioning across neurological conditions
Contact Information
Global Headquarters
Address: 3 Hatnufa St. 6th Fl., P.O. Box 161, Yokneam, 2069203, Israel
Phone: 972 4 9590123
United States Headquarters
Address: 2 Cabot Road, Hudson, MA 01749, USA
Phone: 508-251-1154
Parent Company
Lifeward Ltd operates as an independent, publicly traded entity with no parent company.
Stock: Nasdaq: LFWD
Website: golifeward.com
Investor Relations: ir@golifeward.com
